Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
about
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjectsCYP2C19 polymorphism influences Helicobacter pylori eradicationThe Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian SubjectsCharacterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay)Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancerPopulation pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.Implementing genotype-guided antithrombotic therapy.Association of CYP2C19*2 and *3 genetic variants with essential hypertension in KoreansMetabolism of profenofos to 4-bromo-2-chlorophenol, a specific and sensitive exposure biomarker.Pharmacogenetics in Jewish populations.CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary interventionInactive alleles of cytochrome P450 2C19 may be positively selected in human evolutionA pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activityAllele and genotype frequency of CYP2C19 in a Tamilian population.Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjectsIdentification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card systemAllele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese populationClinical Application of CYP2C19 Pharmacogenetics Toward More Personalized MedicineCYP2C19 drug-drug and drug-gene interactions in ED patients.CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factorsRapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pyloriPotent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel ResistanceAttempts to enhance the eradication rate of Helicobacter pylori infectionImpact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.
P2860
Q24564755-1BDB37A4-00DD-4F8E-9EF3-D07A57E852F4Q27005916-645F6DB0-3E70-42BD-BE89-3538ABBD4357Q28547386-932606D2-A448-4BE0-A5BF-EE1B30A97167Q30939373-41D7F928-559C-413F-BF6E-45CC21497DBCQ31144283-023BE92F-D240-4640-B949-DBD3F3987239Q33261407-92F4233B-70FB-4C87-A553-FAE3A9136C59Q33608028-0D45796D-E1A9-4C87-BBAA-44796DBE3B52Q33608783-D171EDEB-B96C-41AC-AA81-43461646281AQ33696563-0492CD72-5406-4778-AB51-B321A8B056B3Q33990428-C47B2D6D-5854-48DF-A5D6-6CB33D04EBC1Q34306561-7AAC490A-7B62-4693-AD9D-61236012DFE3Q34328153-9D5FD4BA-8125-48CF-8B34-E92765EA0D49Q34458720-FDBEE7E6-898F-40FC-B2CE-C549620DDDB2Q34552473-D73168AB-C5A1-4472-B72F-7B0D157D808FQ35122933-5D5FF3C7-8CC9-4EF8-ACD3-7A8A2EBE5515Q35137054-17BDCE87-F243-46B1-B952-E796DF2E11E1Q35617669-5EA7C943-41ED-48D5-B955-CB8EF4D00A04Q35803786-748481CC-956E-41D0-B18C-1C4BCA2DE46BQ35825693-1B689DB6-5AC1-4DB0-BE7E-FC2C24609EC1Q35825705-443EA6A9-0195-4018-B89F-43638B78FAD8Q35826268-76972D33-1AA2-4ADB-8842-303D2A2C95CBQ35846595-72CD5E8E-0FC8-4718-B3BC-BB943F2483B7Q36052505-EA7E13FE-5CEB-4709-B348-A2EDF95D681EQ36055226-240B0775-206D-413B-9658-2CACDD718750Q36406247-73325C36-6F89-4498-A2D5-708B36CD9298Q36441521-049EE309-F310-4F07-A91F-CBE37BA563A1Q36475190-17A6F94A-9A5A-4DD5-B845-B2FBDF833EA1Q36535932-4D43D3C0-055D-497C-AB84-BB81355BB526Q36580034-6A5C6FD2-A173-4AFF-8A34-EA637DB544D6Q36930041-D304F163-F3C8-47D3-B56C-A4C98904C2A6Q37140633-2C9C2FC9-9D14-4237-85B7-10D46DA60796Q37162141-0C450239-96B3-4A74-B0D7-75D24B0C3A79Q37176949-1E9EC21C-70A4-4D71-925F-FE1B4E56B334Q37201668-ADFE206A-4548-4C03-9344-0F06E8C812C7Q37204050-136A863C-C0B7-4E87-9FE0-3E2EE445E4D0Q38212213-888741A2-F582-4F05-8DF7-05CA4FD74E2EQ38651234-A5315546-2D1D-472D-AB35-FB98927EEEF2Q38841918-3AC2C1CF-C1D5-42B8-AED6-6E2DF80557B7Q40389903-83CC1336-8D21-4E25-A4AF-01BCCD9096B2Q40675074-EE395837-1959-4A5C-B6D1-B93B5031A1D4
P2860
Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Frequencies of the defective C ...... nd American black populations.
@en
Frequencies of the defective C ...... nd American black populations.
@nl
type
label
Frequencies of the defective C ...... nd American black populations.
@en
Frequencies of the defective C ...... nd American black populations.
@nl
prefLabel
Frequencies of the defective C ...... nd American black populations.
@en
Frequencies of the defective C ...... nd American black populations.
@nl
P2093
P1476
Frequencies of the defective C ...... nd American black populations.
@en
P2093
J A Goldstein
S M de Morais
T Ishizaki
P577
1997-02-01T00:00:00Z